Medicus Pharma (MDCX) has received full regulatory and ethical approvals in the United Kingdom to expand its ongoing Phase 2 clinical study evaluating Doxorubicin Microneedle Array to non-invasively treat basal cell carcinoma of the skin. The phase 2 clinical study which is currently underway in nine clinical sites in United States can now expand into additional sites in United Kingdom. The approvals were issued by the Medicines and Healthcare products Regulatory Agency, the Health Research Authority and the Wales Research Ethics Committee. The MHRA approval followed a comprehensive scientific review of the Investigational Medicinal Product Dossier and protocol. The WREC issued a favorable ethical opinion, and the HRA granted study wide governance approval, confirming compliance with U.K. Good Clinical Practice and National Health Service capacity and capability standards.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDCX:
- Medicus Pharma Ltd’s Strategic Collaboration and Promising Phase 2 Results Justify Buy Rating
- Medicus Pharma Collaborates with Gorlin Syndrome Alliance for SKINJECT™ Access
- Medicus Pharma announces strategic collaboration with Gorlin Syndrome Alliance
- Medicus Pharma Expands Global Clinical Trials for Skin Cancer Treatment
- Medicus Pharma announces first patient treated in UAE SKNJCT-004 Phase 2 study